JP2020514411A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514411A5
JP2020514411A5 JP2019562217A JP2019562217A JP2020514411A5 JP 2020514411 A5 JP2020514411 A5 JP 2020514411A5 JP 2019562217 A JP2019562217 A JP 2019562217A JP 2019562217 A JP2019562217 A JP 2019562217A JP 2020514411 A5 JP2020514411 A5 JP 2020514411A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
cancer
zafirlukast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019562217A
Other languages
English (en)
Japanese (ja)
Other versions
JP7272655B2 (ja
JP2020514411A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/015694 external-priority patent/WO2018140858A1/en
Publication of JP2020514411A publication Critical patent/JP2020514411A/ja
Publication of JP2020514411A5 publication Critical patent/JP2020514411A5/ja
Priority to JP2022199341A priority Critical patent/JP2023030014A/ja
Application granted granted Critical
Publication of JP7272655B2 publication Critical patent/JP7272655B2/ja
Priority to JP2024134797A priority patent/JP2024161023A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019562217A 2017-01-30 2018-01-29 チオールイソメラーゼ阻害剤およびその使用 Active JP7272655B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022199341A JP2023030014A (ja) 2017-01-30 2022-12-14 チオールイソメラーゼ阻害剤およびその使用
JP2024134797A JP2024161023A (ja) 2017-01-30 2024-08-13 チオールイソメラーゼ阻害剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451858P 2017-01-30 2017-01-30
US62/451,858 2017-01-30
PCT/US2018/015694 WO2018140858A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022199341A Division JP2023030014A (ja) 2017-01-30 2022-12-14 チオールイソメラーゼ阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2020514411A JP2020514411A (ja) 2020-05-21
JP2020514411A5 true JP2020514411A5 (https=) 2021-03-11
JP7272655B2 JP7272655B2 (ja) 2023-05-12

Family

ID=62978426

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019562217A Active JP7272655B2 (ja) 2017-01-30 2018-01-29 チオールイソメラーゼ阻害剤およびその使用
JP2022199341A Pending JP2023030014A (ja) 2017-01-30 2022-12-14 チオールイソメラーゼ阻害剤およびその使用
JP2024134797A Pending JP2024161023A (ja) 2017-01-30 2024-08-13 チオールイソメラーゼ阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022199341A Pending JP2023030014A (ja) 2017-01-30 2022-12-14 チオールイソメラーゼ阻害剤およびその使用
JP2024134797A Pending JP2024161023A (ja) 2017-01-30 2024-08-13 チオールイソメラーゼ阻害剤およびその使用

Country Status (6)

Country Link
US (2) US11872210B2 (https=)
EP (1) EP3585809B1 (https=)
JP (3) JP7272655B2 (https=)
BR (1) BR112019015721A2 (https=)
CA (2) CA3282526A1 (https=)
WO (1) WO2018140858A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164874A1 (en) 2018-02-20 2019-08-29 Western New England University Thiol isomerases inhibitors for the treatment and prevention of food allergies, allergic diseases, and inflammatory diseases
CN113289020B (zh) * 2021-05-17 2023-04-18 福州大学 蛋白质二硫键异构酶小分子抑制剂及其应用
AU2022276190A1 (en) 2021-05-19 2024-01-18 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) * 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions
CN120187701A (zh) * 2022-08-19 2025-06-20 西新英格兰大学 硫醇异构酶抑制剂及其制备方法和使用方法
WO2025094946A1 (ja) * 2023-10-30 2025-05-08 国立大学法人東海国立大学機構 抗体又はその抗原結合性断片、がんの治療用キット、及びがんの治療用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4985465A (en) 1989-07-14 1991-01-15 Hendler Sheldon S Method for inhibiting viral and retroviral infections
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
GB9027018D0 (en) 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
ES2333979T3 (es) * 2004-11-22 2010-03-03 Eli Lilly And Company Potenciadores de los receptores del glutamato.
KR100649009B1 (ko) 2004-12-30 2006-11-27 동부일렉트로닉스 주식회사 시모스 이미지 센서의 광감지 소자 및 그의 제조방법
EP3087969B1 (en) 2005-05-20 2021-06-30 Jack L. Arbiser Proteasome inhibitors and uses thereof
WO2007070875A1 (en) 2005-12-15 2007-06-21 Aerosol Science Laboratories, Inc. Treatment of active infections and related compositions
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
DE102007001804A1 (de) 2007-01-12 2008-07-17 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von GABAB-Rezeptor selektiven Agonisten zur Behandlung entzündlicher Hauterkrankungen
EP2269076A4 (en) 2008-03-14 2011-04-06 Nat Jewish Health METHOD FOR DETERMINING THE RECOMMENDATION FOR TREATMENT WITH LEUKOTRIA MODIFIERS
WO2009152454A1 (en) 2008-06-12 2009-12-17 The Johns Hopkins University Methods for treating or preventing brain infections
WO2013055674A1 (en) 2011-10-10 2013-04-18 The University Of Toledo Method for treating infections
US9730921B2 (en) 2012-03-27 2017-08-15 Duke University Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US9616056B2 (en) 2013-03-15 2017-04-11 Institute For Cancer Research Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma
WO2014175253A1 (ja) * 2013-04-22 2014-10-30 株式会社栃木臨床病理研究所 抗腫瘍剤
US20160145209A1 (en) * 2013-06-21 2016-05-26 The Broad Institute, Inc. Compounds and compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
GB201321089D0 (en) * 2013-11-29 2014-01-15 Univ East London Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
WO2016118639A1 (en) * 2015-01-20 2016-07-28 The Trustees Of Columbia University In The City Of New York Small molecule oxidizers of pdi and their use
JP6528314B2 (ja) * 2015-03-20 2019-06-12 国立大学法人山口大学 Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤

Similar Documents

Publication Publication Date Title
JP2020514411A5 (https=)
JP2014077003A5 (https=)
JP2014515373A5 (https=)
Patel et al. Contemporary developments in the discovery of selective factor Xa inhibitors: A review
JP2015057436A5 (https=)
HUE034869T2 (en) Combination therapy with substituted oxazolidinones
JP2009138003A5 (https=)
FI4119569T3 (fi) Konjugoituja antisense-yhdisteitä käytettäviksi hoidossa
TWI377945B (en) Prevention and treatment of thromboembolic disorders
JP2024161023A (ja) チオールイソメラーゼ阻害剤およびその使用
JP2009543844A5 (https=)
JP2018521086A5 (https=)
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
JP2012525358A5 (https=)
JP2021505669A5 (https=)
CN117180245B (zh) 辅酶q10组合物及其制备工艺和在保护心脏中的应用
CN103450087B (zh) 丹皮酚与奥扎格雷偶联物的制备方法
Lyon et al. Temporary control of ventricular arrhythmias by drug-induced sinus tachycardia
JP2020509035A5 (https=)
Thomas et al. Initial studies in man with a novel thromboxane receptor blocking drug GR32191
CN103467383A (zh) 一种丹皮酚与奥扎格雷偶联物及其药物组合物、医药用途
JP2016510738A5 (https=)
WO2021185356A1 (zh) 丁基苯酞及其衍生物的用途
JP2008526816A5 (https=)
WO2014055053A1 (ru) Фармацевтическая композиция 1- адамантилетилокси-з-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии